ADALAT* (nifedipine) Capsules
For Oral Use INDICATIONS AND USAGE: 1. Vasospastic Angina: Adalat (nifedipine) is indicated for the management of vasospasfic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment elevation, 2) angina or coronary artery spasm provoked by ergonovine. or 3) angiographically demonstrated coronary artery spasm In those patients who have hod angiography. the presence of significant fixed obstructive disease is not incompatible with fhe diagnosis of vasospastic angino. provided that fhe above criteria are satisfied ADALAT may also be used where the clinical presentation suggests a possible vasospastic component but where vasospasm hos not been confirmed, e g . where pain has a variable threshold on exertion or in unstable angina where electrocardiographic findings are compatible with intermittent vasospasm, or when angino is retracfory to nitrates and/or adequate doses of beta blockers II. Chronic Stable Angina (Classical Effort-Associated Angina): ADALAT is indicated for the management of chronic stable angina (effort-associated angina) without evidence of vosospasm in patients who remain symptomatic despite adequate doses of beta blockers and/or organic nitrates or who cannot tolerate those agents In chronic stable angina (effort-associated angina) ADALAT has been effective in controlled trials of up to eight weeks duration in reducing angina frequency and increasing exercise tolerance, but confirmation of sustained effectiveness and evaluation of long-term safety in these patients are incomplete Controlled studies in small numbers of patients suggest concomitant use of ADALAT and beta-blocking agents may be beneficial in patients with chronic stable angina, buf available information is not sufficient to predict with confidence the effects ot concurrent treotmenl, especially in patients with compromised left ventricular function or cardiac conduction abnormalities When introducing such concomitant therapy, care must be taken to monitor blood pressure closely since severe hypotension can occur from the combined effects of the drugs (See WARNINGS ) Contraindications: Known hypersensitivity reaction to ADALAT Warnings: Excessive Hypotension: Although in most patients, the hypotensive effect of ADALAT is modest and well tolerated, occasional patients have had excessive and poorly tolerated hypotension These responses have usually occurred during initial titralion or at the time of subsequent upward dosage adjustment, and may be more likely in patients on concomitant beta blockers Severe hypotension and/or increased fluid volume requirements have been reported in patients receiving ADALAT together with a beta blocking agent who underwent coronary artery bypass surgery using nigh dose tentanyl anesthesia The interaction with high dose fentonyl appears to be due to the combination of ADALAT and a beta blocker, but the possibility that it may occur with ADALAT alone, with low doses of tentanyl, mother surgicol procedures, or with other narcotic analgesics cannot be ruled out In ADALAT treated panents where surgery using high dose fentanyl anesthesia is contemplated, fhe physician should be aware of these potential problems and, if the patient's condition permits, sufficient time (at least 36 hours) should be allowed for ADALAT to be washed out of the body prior to surgery Increased Angina: Occasional patients have developed well documented increased fre quency, duration or severity of angino on starting ADALAT or at the time of dosage increases The mechanism of this response is not established but could result from decreased coronary perfusion associated with decreased diastolic pressure with increased heart rate, or from increased demand resulting from increased heart rote alone Beta Blocker Wittidrawol: Patients recently withdrawn from beta blockers may develop a withdrawal syndrome with increased angina, probably related fo increased sensitivity to catecholamines Initiation of ADALAT treatment will not prevent this occurrence and might be expected to exacerbate it by provoking reflex catecholomine release There hove been occasional reports ot increased angina in a setting of beta blocker withdrawal and ADALAT initiation II is important to taper beta blockers if possible, rather than stopping them abruptly before beginning ADALAT Congestive Heart Failure: Rarely, patients, usually receiving a beta blocker, have developed heart failure after beginning ADALAT Patients with tight aortic stenosis may be at greater risk for such on event PRECAUTIONS: General: Hypotension: Because ADALAT decreases peripheral vascular resistance, careful monitoring of blood pressure during the initial administration and titration of ADALAT is suggested Close observation is especially recommended for patients already taking medications that are known to lower blood pressure (See WARN-INGS ) Peripheral edema: Mild to moderate peripheral edema, typically associated with ar terial vasodilafion and not due to left ventricular dysfunction, occurs in about one in ten patients treated with ADALAT This edema occurs primarily in the lower extremities ond usually responds to diuretic therapy With patients whose angina is complicated by congestive heart failure, care should be taken to differentiate this peripheral edema from the effects ot increasing left ventricular dysfunction Laboratory tests: Rare, usually transient, but occasionally significant elevations of enzymes such as alkaline phosphatase.
CPK, LDH, SGOT and SGPT have been noted The relationship to ADALAT (nifedipine) therapy is uncertain in most cases, but probable in some These laboratory abnormalities have rarely been associated with clinical symptoms, however, cholestasis with or without laun dice has been reported Rare instances of allergic hepatitis have been reported Limited din ical studies have demonstrated a moderate but statistically significant decrease in platelet aggregation and increase in bleeding time in some ADALATpatients No clinical significance for these findings has been demonstrated. Although ADALAT has been used safely in patients with renol dysfunction and has been reported to exert a beneficial effect in certain cases, rare, reversible elevations in BUN and serum creatinine have been reported in patients with pre-existing chronic renoJ insufficiency The relationship to ADALAT therapy is uncertain in most cases, but probable in some Drug Interactions: Beto-odrenergic blocking agents (See Indications and warnings ) Experience in over 1400 patients in a non-comparative clinical trial has shown that concomitant administration of ADALAT and beta-blocking agents is usually well tolerated, but there have been occasional literature reports suggesting that the combination may increase the likelihood of congestive heart failure, severe hypotension or exacerbation of angina Long-acting nitrates ADALAT may be safely co-odministered with nitrates, but there have been no controlled studies to evaluate the antianginal effectiveness of this combination Digitalis: Administration of ADALAT with digoxin increased digoxin lev els in nine of twelve normal volunteers The average increase was 45% Another investigator found no increase in digoxin levels in thirteen patients with coronary artery disease m an uncontrolled study of over two hundred patients with congestive heart failure during which digoxin blood levels were not measured, digitalis toxicity was not observed Since there have been isolated reports of patients with elevated digoxin levels, it is recommended thai digoxin levels be monitored when initiating, adjusting, and discontinuing ADALAT to avoid possible over-or under-digitahzation Coumann anticoagulants There have been rare reports ol increased prothrombin time in patients faking coumorin anticoagulants to whom ADALAT was administered Cimetidme A study in six healthy volunteers hos shown o sig nificant increase in peak nifedipine plasma levels (80%) and area-under-the-curve (74%) after a one week course of cimelidine ot 1000 mg per day ond nifedipine at 40 me per day Ranitidine produced smaller, non-significant increases If nifedipine therapy is initiated in a patient currently receiving ametidine, cautious titration is advised Carcinogenesis. mutagenesls, impairment of fertility: Nifedipine was administered orally to rats for two years and was not shown to be carcinogenic When given to rats prior to mating, nifedipine caused reduced fertility at a dose approximately 30 limes the maximum recommended humon dose In vivo mutageniaty studies were negative Pregnancy: Pregnoncy Category C Nifedipine has been shown to be teratogenic in rats and embryotoxic in rats, mice and rabbits There are no adequate and well controlled studies in pregnant women ADALAT should De used dunnq pregnancy only if the potential benefit justifies the potential risk to the fetus ADVERSE REACTIONS: The most common adverse events include dizziness or lightheod edness, peripheral edema, nausea, weakness, headache and flushing, each occurring in about 10% ot patients, transient hypotension in about 5%. palpitation in obout 2% and syncope in about 0 5% Syncopal episodes did not recur with reduction in the dose ot ADALAT or concomitant antianginal medication Additionally, the following have been reported muscle cramps, nervousness, dyspnea, nasal and chest congestion, shortness of breath, diarrhea, constipation, gastrointestinal cramps, flatulence, inflammation, joint stiffness, shakiness, jittenness. sleep disturbances, blurred vision, difficulties in balance, dermatitis, pruritus, urticaria, tever, sweating, chills, sexual difficulties, thrombocytopema. anemia, leukopenia. purpura. allergic hepatitis, gingival hyperplasia, and erythromelalgio Very rarely, introduction of ADALAT therapy was associated with on increase in anginal pain, pos sibly due to associated hypotension In addition, more serious adverse events were oo served, not readily distinguishable from the natural history of the disease in these patients It remains possible, however, that some or many of these events were drug related Myo cardial infarction occurred in about 4% of patients and congestive heart failure or pulmo nary edemo in about 2% Ventricular arrhythmias or conduction disturbances eoch occurred in fewer than 0 5% of patients HOW SUPPLIED: Each orange, soft gelatin ADALAT CAPSULE contains 10 mg ot nifedipine ADALAT CAPSULES are supplied in bottles of 100 (NDC0O26 8811 -51) 300 (NDC0026 8811 18), and unit dose (10 xlO 
